Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.

Fráňová J, Fingerhutová Š, Kobrová K, Srp R, Němcová D, Hoza J, Uher M, Saifridová M, Linková L, Doležalová P.

Pediatr Rheumatol Online J. 2016 Jun 14;14(1):36. doi: 10.1186/s12969-016-0099-z.

2.

Advances in the treatment of polyarticular juvenile idiopathic arthritis.

Webb K, Wedderburn LR.

Curr Opin Rheumatol. 2015 Sep;27(5):505-10. doi: 10.1097/BOR.0000000000000206. Review.

3.

Genetic determinants for methotrexate response in juvenile idiopathic arthritis.

Pastore S, Stocco G, Favretto D, De Iudicibus S, Taddio A, d'Adamo P, Malusà N, Addobbati R, Decorti G, Lepore L, Ventura A.

Front Pharmacol. 2015 Mar 23;6:52. doi: 10.3389/fphar.2015.00052. eCollection 2015. Review.

4.

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.

van Dijkhuizen EH, Wulffraat NM.

Pediatr Rheumatol Online J. 2014 Dec 11;12:51. doi: 10.1186/1546-0096-12-51. eCollection 2014. Review.

5.

Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.

Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V, Medeiros R.

Biomed Res Int. 2014;2014:368681. doi: 10.1155/2014/368681. Epub 2014 May 21.

6.

Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases.

Cobb J, Cule E, Moncrieffe H, Hinks A, Ursu S, Patrick F, Kassoumeri L, Flynn E, Bulatović M, Wulffraat N, van Zelst B, de Jonge R, Bohm M, Dolezalova P, Hirani S, Newman S, Whitworth P, Southwood TR, De Iorio M; Childhood Arthritis Response to Medication Study (CHARMS); Childhood Arthritis Prospective Study (CAPS); BSPAR study group, Wedderburn LR, Thomson W.

Pharmacogenomics J. 2014 Aug;14(4):356-64. doi: 10.1038/tpj.2014.3. Epub 2014 Apr 8.

7.

Current developments in the use of biomarkers for juvenile idiopathic arthritis.

Duurland CL, Wedderburn LR.

Curr Rheumatol Rep. 2014 Mar;16(3):406. doi: 10.1007/s11926-013-0406-3. Review.

8.

Mothers' reports of the difficulties that their children experience in taking methotrexate for Juvenile Idiopathic Arthritis and how these impact on quality of life.

Mulligan K, Kassoumeri L, Etheridge A, Moncrieffe H, Wedderburn LR, Newman S.

Pediatr Rheumatol Online J. 2013 May 28;11(1):23. doi: 10.1186/1546-0096-11-23.

9.

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Romão VC, Canhão H, Fonseca JE.

BMC Med. 2013 Jan 23;11:17. doi: 10.1186/1741-7015-11-17. Review.

10.

Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?

Halilova KI, Brown EE, Morgan SL, Bridges SL Jr, Hwang MH, Arnett DK, Danila MI.

Int J Rheumatol. 2012;2012:978396. doi: 10.1155/2012/978396. Epub 2012 Jul 9.

11.

Global tests of P-values for multifactor dimensionality reduction models in selection of optimal number of target genes.

Dai H, Bhandary M, Becker M, Leeder JS, Gaedigk R, Motsinger-Reif AA.

BioData Min. 2012 May 22;5(1):3. doi: 10.1186/1756-0381-5-3.

Items per page

Supplemental Content

Write to the Help Desk